Weigert, Raha
Hetzel, Sara https://orcid.org/0000-0002-4783-3814
Bailly, Nina
Haggerty, Chuck
Ilik, Ibrahim A.
Yung, Philip Yuk Kwong
Navarro, Carmen
Bolondi, Adriano https://orcid.org/0000-0002-1096-9435
Kumar, Abhishek Sampath https://orcid.org/0000-0001-7918-6706
Anania, Chiara
Brändl, Björn
Meierhofer, David
Lupiáñez, Darío G.
Müller, Franz-Josef https://orcid.org/0000-0001-9478-8430
Aktas, Tugce https://orcid.org/0000-0003-1599-9454
Elsässer, Simon J. https://orcid.org/0000-0001-8724-4849
Kretzmer, Helene
Smith, Zachary D. https://orcid.org/0000-0002-9283-1957
Meissner, Alexander https://orcid.org/0000-0001-8646-7469
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (DP2HD108774)
Max-Planck-Gesellschaft
Article History
Received: 16 May 2022
Accepted: 21 February 2023
First Online: 6 April 2023
Competing interests
: A.M. and Z.D.S. are inventors on a patent related to hypermethylated CGI targets in cancer. Z.D.S. and A.M. are co-founders and scientific advisors of Harbinger Health. The remaining authors declare no competing interests.